Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Treatment in Pediatric Lower Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum weight of 10 kg/22 lb~* Cerebral palsy with dynamic muscle contracture /spasticity of the ankle~Exclusion Criteria:~* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease~* Uncontrolled epilepsy~* Botulinum Toxin therapy of any serotype for any condition within the last 6 months~* History of surgical intervention of the lower study leg or planned surgery of any limb during the study~* Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected upper limb during the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® 4 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
- BOTOX® 8 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
- Normal Saline (Placebo) (Type: PLACEBO_COMPARATOR): Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.

Based on this trial design, predict the completion outcome and termination type (if applicable).